Compare MATH & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MATH | QTTB |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.8M | 44.3M |
| IPO Year | 2016 | 2018 |
| Metric | MATH | QTTB |
|---|---|---|
| Price | $1.09 | $5.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 26.4K | ★ 359.5K |
| Earning Date | 07-30-2025 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | N/A | ★ 2.42 |
| Revenue | N/A | ★ $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.10 | ★ $2.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $1.38 |
| 52 Week High | $4.17 | $8.05 |
| Indicator | MATH | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 49.08 |
| Support Level | $1.00 | $5.51 |
| Resistance Level | $1.30 | $6.37 |
| Average True Range (ATR) | 0.09 | 0.91 |
| MACD | 0.01 | -0.19 |
| Stochastic Oscillator | 21.12 | 14.60 |
Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.